

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Liver cancer	Purinergic receptor P2Y G protein-coupled 2 (P2RY2; P2Y2)	Cell culture and mouse studies suggest antagonizing P2Y2 could be useful for treating liver cancer. Human hepatocellular carcinoma (HCC) cells had higher P2Y2 levels than normal hepatocytes. In cultured HCC cells, P2Y2-targeting shRNA or a P2Y2 antagonist decreased proliferation and migration compared with control shRNA or vehicle. In a mouse xenograft model of HCC, P2Y2-targeting shRNA or a P2Y2 antagonist decreased tumor growth. Next steps could include identifying potent and selective P2Y2 antagonists.	Patent and licensing status undisclosed	Xie, R. <i>et al. J. Biol. Chem.</i> ; published online May 20, 2014; doi:10.1074/jbc.M113.540047 Contact: Biguang Tuo, Zunyi Medical College, Zunyi, China e-mail: tuobiguang@aliyun.com Contact: Hui Dong, same affiliation as above e-mail: h2dong@ucsd.edu
		SciBX 7(26); doi:10.1038/scibx.2014.763 Published online July 10, 2014		